Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Dose-escalation, Single-Center, Open-labeled Study to Evaluate the Safety and Tolerability of Human Induced Pluripotent Stem Cell-derived Human Forebrain Neural Progenitor Cell Injection (hNPC01) in Chronic Ischemic Stroke

Next Previous
Trial Profile

A Phase 1 Dose-escalation, Single-Center, Open-labeled Study to Evaluate the Safety and Tolerability of Human Induced Pluripotent Stem Cell-derived Human Forebrain Neural Progenitor Cell Injection (hNPC01) in Chronic Ischemic Stroke

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Feb 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs HNPC 01 (Primary)
  • Indications Ischaemic stroke
  • Focus Adverse reactions
  • Sponsors Hopstem Biotechnology

Most Recent Events

  • 21 Jan 2026 Results presented in the Hopstem biotechnology Media Release.
  • 21 Jan 2026 According to a Hopstem biotechnology media release, based on the positive data from the Phase 1 clinical trials in China, FDA has approved Hopstem to initiate a dose-bridging, randomized-controlled, double-blinded, Phase 2 clinical trial in the United States. Hopstem can further determine the key design elements of the Phase 3 clinical trial, such as sample size, in collaboration with the FDA, and then directly expand the Phase 2 trial into the final pivotal 2/3 study
  • 12 Mar 2024 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top